HC Wainwright & Co. Maintains Buy on Mainz Biomed, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on Mainz Biomed (NASDAQ:MYNZ) but has reduced the price target from $9 to $5.
November 20, 2023 | 11:11 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. analyst Yi Chen reaffirms a Buy rating on Mainz Biomed but decreases the price target from $9 to $5.
The reduction in price target by a reputable analyst could lead to a negative short-term sentiment among investors, potentially causing a decrease in the stock price. However, the maintenance of a Buy rating suggests underlying confidence in the company's fundamentals, which may mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100